JAN 16, 2019 9:00 AM PST

Predicting Response to Intravesical Immunotherapy with BCG

Sponsored by: Abbott Molecular
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor of Urology and Director of Urologic Oncology Fellowship, M.D. Anderson Cancer Center
    Biography
      Dr Ashish M. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at M.D. Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr Kamat's expertise is in multidisciplinary management of urologic cancers with an emphasis bladder and prostate cancer, organ sparing therapies, minimally invasive techniques, and orthotopic bladder substitution (neobladder). While he is a busy surgeon, he maintains an active research portfolio to improve the care of patients. Dr Kamat's efforts are directed towards identifying predictors of response to therapy - especially immunotherapy - as a first step towards personalized cancer therapeutics. A major focus of his laboratory research is to develop novel treatments for bladder cancer and identify resistance mechanisms and ways to overcome them. He serves as project PI on the MD Anderson Cancer Center GU (Bladder) SPORE. He has authored over 200 publications, editorials & book chapters in prestigious journals; he is listed in'Who's Who in Medicine' and 'Best Doctors in America' and has won the Compassionate Doctor Award from patient groups. He is an exceptional educator nominated twice for the Robert M. Chamberlain Distinguished Mentor Award and has been invited as a visiting professor to several universities across the world. Dr Kamat is also Co President,International Bladder Cancer Network, Chair, Bladder Cancer Think Tank (2015), Chair, Bladder Cancer Task Force for SITC, actively participates in various global urologic efforts, and serves on the board of regional and national societies for Urology.

    Abstract

    DATE: January 16th, 2019

    TIME: 9:00AM PST, 12:00PM EST

    Dr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care, to examine patient outcomes in the BCG response monitoring scenario.

    Learning Objectives:

    • Review of Bladder Cancer case studies to understand the use of BCG in bladder cancer subtypes
    • Understand BCG tolerance, patient response, and use of UroVysion

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees
    • See more